Skip to Content

Therapeutics Science: DaxibotulinumtoxinA for Injection

DaxibotulinumtoxinA for Injection is an investigational agent being evaluated for therapeutic uses in muscle movement and pain disorders, two categories that have a range of available treatment options that do not offer long-term relief. Clinical trials are currently underway in cervical dystonia, adult upper limb spasticity and plantar fasciitis, with plans to study migraine.

Plantar Fasciitis

In December 2019, Revance completed enrollment of its Phase 2 placebo-controlled clinical trial of DaxibotulinumtoxinA for Injection for the management of plantar fasciitis. Plantar fasciitis is characterized by inflammation and sharp, constant pain in the heel that can become incapacitating. The company expects to report topline results for the Phase 2 trial in the second half of 2020.

Cervical Dystonia

Completed patient enrollment of the Revance’s pivotal ASPEN-1 Phase 3 clinical trial evaluating DaxibotulinumtoxinA for Injection for the treatment of isolated cervical dystonia (CD), a movement disorder affecting the neck, was announced in November 2019. Topline results are expected in the second half of 2020.

Adult Upper Limb Spasticity

The JUNIPER Phase 2 Trial for treatment of adult upper limb spasticity is currently underway. Upper limb spasticity is a form of movement disorder that presents as increased tone or stiffness of the muscles affecting a patient’s ability to produce or control voluntary movement in the arms and hands.

Migraine

Revance is also investigating the use of DaxibotulinumtoxinA for Injection for migraines. Potential timing of clinical studies and the path forward is currently being evaluated.

Therapeutics Clinical Program Update

  • PRECLINICAL
  • PHASE 1
  • PHASE 2
  • PHASE 3

DaxibotulinumtoxinA for Injection — Therapeutics

Cervical Dystonia
PHASE 3 COMPLETE
Upper Limb Spasticity
IN PHASE 2
Plantar Fasciitis
IN PHASE 2
CD and PF Readouts in 2H 2020
Back to top